ArticleGastroenterology and hepatology from bed to bench2012
Estimation of average diagnosis and treatment costs of hepatitis C.
Article in Gastroenterology and hepatology from bed to bench, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- The Estimation of Economic Burden of Hepatitis C Virus Infection in Iran.Iranian journal of public health · 2018Article
- The critical role of injecting drug users on the spatial distribution of hepatitis C virus; a study in the West of Iran.Gastroenterology and hepatology from bed to bench · 2018Article
- Economic Burden of Hepatitis C Virus Infection in Different Stages of Disease: A Report From Southern Iran.Hepatitis monthly · 2016Article
- Hepatocellular carcinoma in Asia: Prevention strategy and planning.World journal of hepatology · 2015Article
- Epidemiological features of hepatitis B and C infection in a high risk population: results of screening programs.Gastroenterology and hepatology from bed to bench · 2013Article
- Evaluated outcomes in patients with Chronic Hepatitis C.Gastroenterology and hepatology from bed to bench · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe objective of this study was to estimate the average cost of diagnosis and treatment of hepatitis C among patients based on their treatment regime, during the one course of treatment and six-month after stopping that.
backgroundHepatitis C virus (HCV) infection is a major cause of liver-related morbidity and mortality worldwide and a major public health problem. PATIENTS AND
methodsAll data for this cross-sectional study were collected from medical records of 200 patients with hepatitis C, who referred to a private gastroenterology clinic between years 2005 through 2009. Information related to the 200 patients was extracted from their medical records and finally, 77 patients of them, who their treatment was not interfering with any other disease entered in this study. Therefore diagnosis and treatment costs of these patients were calculated. Attributable costs were reported as purchasing power parity dollars (PPP$).
resultsMean costs of diagnosis and treatment in one course of treatment and six month after that with standard interferon plus ribavirin (INF-RBV) exceeds 3,850 PPP$ and for patients who treated with peg-interferon plus ribavirin (PEG-RIBV) was 16,494 PPP$. Also in both types of treatment, medication cost was found to be a dominant cost component.
conclusionHepatitis C represents a very important and potentially costly disease to managed care organizations. Patients with this disease require expensive drug therapies and consume significant health care resources.
Indexed as
Identifiers
24834215PMC4017475What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.